This company has been acquired
Resumen de acción CEMI
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Chembio Diagnostics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.24 |
| 52 Week Low | US$0.19 |
| Beta | 1.86 |
| 1 Month Change | 16.40% |
| 3 Month Change | 29.96% |
| 1 Year Change | -24.68% |
| 3 Year Change | -96.42% |
| 5 Year Change | -94.31% |
| Change since IPO | -99.70% |
Noticias y actualizaciones recientes
Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02Rentabilidad de los accionistas
| CEMI | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 1.1% | -2.9% | -3.2% |
| 1Y | -24.7% | -3.7% | 19.3% |
Rentabilidad vs. Industria: CEMI underperformed the US Medical Equipment industry which returned -0.1% over the past year.
Rentabilidad vs. Mercado: CEMI underperformed the US Market which returned -5.3% over the past year.
Volatilidad de los precios
| CEMI volatility | |
|---|---|
| CEMI Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CEMI's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: CEMI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1985 | 188 | Richard Eberly | chembio.com |
Resumen de fundamentos de Chembio Diagnostics, Inc.
| Estadísticas fundamentales de CEMI | |
|---|---|
| Capitalización bursátil | US$16.71m |
| Beneficios(TTM) | -US$23.29m |
| Ingresos (TTM) | US$49.52m |
0.3x
Ratio precio-ventas (PS)-0.7x
Ratio precio-beneficio (PE)¿Está CEMI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CEMI | |
|---|---|
| Ingresos | US$49.52m |
| Coste de los ingresos | US$45.65m |
| Beneficio bruto | US$3.88m |
| Otros gastos | US$27.17m |
| Beneficios | -US$23.29m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.63 |
| Margen bruto | 7.83% |
| Margen de beneficio neto | -47.03% |
| Ratio deuda/patrimonio | 104.4% |
¿Cómo se ha desempeñado CEMI a largo plazo?
Ver rendimiento histórico y comparativa